Evidence map›Paper›PMID 32962699›Full record

ArticleBMC cancer2020

AHRR methylation in heavy smokers: associations with smoking, lung cancer risk, and lung cancer mortality.

Laurie Grieshober, Stefan Graw, Matt J Barnett, Mark D Thornquist, Gary E Goodman, Chu Chen, Devin C Koestler, Carmen J Marsit, Jennifer A Doherty

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Blood LeukocyteCancer research communications · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Laurie GrieshoberDepartment of Population Health Sciences, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Room 4746, Salt Lake City, UT, 84112, USA. laurie.grieshober@hci.utah.edu.ORCID http://orcid.org/0000-0003-2316-9143
Stefan GrawDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Matt J BarnettProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Mark D ThornquistProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gary E GoodmanProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Chu ChenProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Devin C KoestlerDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Carmen J MarsitDepartment of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Jennifer A DohertyDepartment of Population Health Sciences, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Room 4746, Salt Lake City, UT, 84112, USA.
Fred Hutch Cancer Center · USEmory University · USUniversity of Utah · USUniversity of Kansas Medical Center · USUniversity of Washington · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SUSAN J. BROWN · 2012 to 2026
$63.0M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOLE L NOLLEN · 2012 to 2026
$40.1M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ANDREW K. GODWIN · 2019 to 2026
$21.5M
THE CAROTENE AND RETINOL EFFICACY TRIAL (CARET)U01CA063673 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 1994 to 2006
$13.0M
Infrastructure Support and Pilot Tissue Collection for the CARET BiorepositoryU01CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEUHOUSER, MARIAN L · 2018 to 2022
$2.9M
INFRASRUCTURE SUPPORT AND DATA ENHANCEMENTS FOR THE CARET BIOREPOSITORYUM1CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 2013 to 2017
$2.8M
Telomeres and lung cancer incidence and survivalR01CA151989 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DOHERTY, JENNIFER A. · 2011 to 2014
$2.4M
MOLECULAR EPIDEMIOLOGY OF LUNG CANCERR01CA111703 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHEN, CHU · 2006 to 2010
$2.2M
NRSA Training CoreTL1TR002540 · NCATS · UNIVERSITY OF UTAH · PI FAGERLIN, ANGELA, FAIRFAX, KEKE CELESTE · 2018 to 2022
$1.6M
NCATS NIH HHS TL1 TR002540NCI NIH HHS P30 CA042014NCI NIH HHS P30 CA168524NCI NIH HHS R01 CA111703NCI NIH HHS R01 CA151989NCI NIH HHS U01 CA063673NCI NIH HHS U01 CA167462NCI NIH HHS U01 CA63673NCI NIH HHS UM1 CA167462NIGMS NIH HHS P20 GM103418NIGMS NIH HHS P20 GM130423
6 · The paper itself

Abstract

backgroundA low level of methylation at cg05575921 in the aryl-hydrocarbon receptor repressor (AHRR) gene is robustly associated with smoking, and some studies have observed associations between cg05575921 methylation and increased lung cancer risk and mortality. To prospectively examine whether decreased methylation at cg05575921 may identify high risk subpopulations for lung cancer screening among heavy smokers, and mortality in cases, we evaluated associations between cg05575921 methylation and lung cancer risk and mortality, by histotype, in heavy smokers.

methodsThe β-Carotene and Retinol Efficacy Trial (CARET) included enrollees ages 45-69 with ≥ 20 pack-year smoking histories and/or occupational asbestos exposure. A subset of CARET participants had cg05575921 methylation available from HumanMethylationEPIC assays of blood collected on average 4.3 years prior to lung cancer diagnosis in cases. Cg05575921 methylation β-values were treated continuously for a 10% methylation decrease and as quintiles, where quintile 1 (Q1, referent) represents high methylation and Q5, low methylation. We used conditional logistic regression models to examine lung cancer risk overall and by histotype in a nested case-control study including 316 lung cancer cases (diagnosed through 2005) and 316 lung cancer-free controls matched on age (±5 years), sex, race/ethnicity, enrollment year, current/former smoking, asbestos exposure, and follow-up time. Mortality analyses included 372 lung cancer cases diagnosed between 1985 and 2013 with available methylation data. We used Cox proportional hazards models to examine mortality overall and by histotype.

resultsDecreased cg05575921 methylation was strongly associated with smoking, even in our population of heavy smokers. We did not observe associations between decreased pre-diagnosis cg05575921 methylation and increased lung cancer risk, overall or by histotype. We observed linear increasing trends for lung cancer-specific mortality across decreasing cg05575921 methylation quintiles for adenocarcinoma and small cell carcinoma (P-trends = 0.01 and 0.04, respectively).

conclusionsIn our study of heavy smokers, decreased cg05575921 methylation was strongly associated with smoking but not increased lung cancer risk. The observed association between cg05575921 methylation and increased mortality in adenocarcinoma and small cell histotypes requires further examination. Our results do not support using decreased cg05575921 methylation as a biomarker for lung cancer screening risk stratification.

Indexed as

DNA MethylationAgedBasic Helix-Loop-Helix ProteinsCase-Control StudiesEarly Detection of CancerFemaleGenetic Predisposition to DiseaseHumansLung NeoplasmsMaleMiddle AgedRandomized Controlled Trials as TopicRepressor ProteinsSmokingSurvival AnalysisUnited StatesAHRR protein, humanBasic Helix-Loop-Helix ProteinsRepressor ProteinsAHRRBiomarkers/serum biomarkersCARETEpidemiologyLung cancerMethylationMortality

Identifiers

PMID32962699
PMCPMC7510160
OpenAlexW3088651631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.